APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chemotheraphy-induced Nausea and Vomitting Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Outlook and Growth Opportunities 2026

30 December 2025205 pages

Choose your research edition.

Industry ResearchChemotheraphy-induced Nausea and Vomitting Treatment Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotheraphy-induced Nausea and Vomitting Treatment Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Chemotheraphy-induced Nausea and Vomitting Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chemotheraphy-induced Nausea and Vomitting Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chemotheraphy-induced Nausea and Vomitting Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chemotheraphy-induced Nausea and Vomitting Treatment market include Eisai, Merck & Co, GlaxoSmithKline, Tesaro, Orchid Healthcare, OPKO Health, Mylan Pharmaceuticals, Mundipharma and Heron Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Chemotheraphy-induced Nausea and Vomitting Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chemotheraphy-induced Nausea and Vomitting Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chemotheraphy-induced Nausea and Vomitting Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Chemotheraphy-induced Nausea and Vomitting Treatment market.

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Company

Eisai

Merck & Co

GlaxoSmithKline

Tesaro

Orchid Healthcare

OPKO Health

Mylan Pharmaceuticals

Mundipharma

Heron Therapeutics

Helsinn

F.Hoffmann La Roche

Especificos Stendhal

Baxter Healthcare

Barr Laboratories

Aphios

Acacia Pharma

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Type

5-HT3 Inhibitors

NK1 Inhibitors

Others

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Application

Delayed Nausea and Vomitting Treatment

Acute Nausea and Vomitting Treatment

Anticipatory Nausea and Vomitting Treatment

Chemotheraphy-induced Nausea and Vomitting Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Chemotheraphy-induced Nausea and Vomitting Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Chemotheraphy-induced Nausea and Vomitting Treatment key companies, revenue, market share, and recent developments.

3. To split the Chemotheraphy-induced Nausea and Vomitting Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Chemotheraphy-induced Nausea and Vomitting Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chemotheraphy-induced Nausea and Vomitting Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Chemotheraphy-induced Nausea and Vomitting Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotheraphy-induced Nausea and Vomitting Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotheraphy-induced Nausea and Vomitting Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotheraphy-induced Nausea and Vomitting Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chemotheraphy-induced Nausea and Vomitting Treatment industry.

Chapter 3: Detailed analysis of Chemotheraphy-induced Nausea and Vomitting Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Chemotheraphy-induced Nausea and Vomitting Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Chemotheraphy-induced Nausea and Vomitting Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends Table 2. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Drivers Table 3. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Opportunities and Challenges Table 4. Chemotheraphy-induced Nausea and Vomitting Treatment Industry Restraints Table 5. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Company (2021-2026) Table 7. Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Chemotheraphy-induced Nausea and Vomitting Treatment Company, Product Type & Application Table 10. Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Chemotheraphy-induced Nausea and Vomitting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 5-HT3 Inhibitors Table 15. Significant Companies of NK1 Inhibitors Table 16. Significant Companies of Others Table 17. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type (2021-2026) Table 21. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Delayed Nausea and Vomitting Treatment Table 23. Significant Companies of Acute Nausea and Vomitting Treatment Table 24. Significant Companies of Anticipatory Nausea and Vomitting Treatment Table 25. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application (2021-2026) Table 29. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application (2027-2032) Table 30. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Region (2021-2026) Table 33. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Region (2027-2032) Table 35. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Market Share by Country (2027-2032) Table 40. Eisai Company Information Table 41. Eisai Business Overview Table 42. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 44. Eisai Recent Development Table 45. Merck & Co Company Information Table 46. Merck & Co Business Overview Table 47. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 49. Merck & Co Recent Development Table 50. GlaxoSmithKline Company Information Table 51. GlaxoSmithKline Business Overview Table 52. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 54. GlaxoSmithKline Recent Development Table 55. Tesaro Company Information Table 56. Tesaro Business Overview Table 57. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 59. Tesaro Recent Development Table 60. Orchid Healthcare Company Information Table 61. Orchid Healthcare Business Overview Table 62. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 64. Orchid Healthcare Recent Development Table 65. OPKO Health Company Information Table 66. OPKO Health Business Overview Table 67. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 69. OPKO Health Recent Development Table 70. Mylan Pharmaceuticals Company Information Table 71. Mylan Pharmaceuticals Business Overview Table 72. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 74. Mylan Pharmaceuticals Recent Development Table 75. Mundipharma Company Information Table 76. Mundipharma Business Overview Table 77. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 79. Mundipharma Recent Development Table 80. Heron Therapeutics Company Information Table 81. Heron Therapeutics Business Overview Table 82. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 84. Heron Therapeutics Recent Development Table 85. Helsinn Company Information Table 86. Helsinn Business Overview Table 87. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 89. Helsinn Recent Development Table 90. F.Hoffmann La Roche Company Information Table 91. F.Hoffmann La Roche Business Overview Table 92. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 94. F.Hoffmann La Roche Recent Development Table 95. Especificos Stendhal Company Information Table 96. Especificos Stendhal Business Overview Table 97. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 99. Especificos Stendhal Recent Development Table 100. Baxter Healthcare Company Information Table 101. Baxter Healthcare Business Overview Table 102. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 104. Baxter Healthcare Recent Development Table 105. Barr Laboratories Company Information Table 106. Barr Laboratories Business Overview Table 107. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 109. Barr Laboratories Recent Development Table 110. Aphios Company Information Table 111. Aphios Business Overview Table 112. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 114. Aphios Recent Development Table 115. Acacia Pharma Company Information Table 116. Acacia Pharma Business Overview Table 117. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio Table 119. Acacia Pharma Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Chemotheraphy-induced Nausea and Vomitting Treatment Product Image Figure 2. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 5-HT3 Inhibitors Image Figure 8. NK1 Inhibitors Image Figure 9. Others Image Figure 10. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type (2021-2032) Figure 13. Delayed Nausea and Vomitting Treatment Image Figure 14. Acute Nausea and Vomitting Treatment Image Figure 15. Anticipatory Nausea and Vomitting Treatment Image Figure 16. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • 5-HT3 Inhibitors
  • NK1 Inhibitors
  • Others
Applications
  • Delayed Nausea and Vomitting Treatment
  • Acute Nausea and Vomitting Treatment
  • Anticipatory Nausea and Vomitting Treatment
Companies covered
  • Eisai
  • Merck & Co
  • GlaxoSmithKline
  • Tesaro
  • Orchid Healthcare
  • OPKO Health
  • Mylan Pharmaceuticals
  • Mundipharma
  • Heron Therapeutics
  • Helsinn
  • F.Hoffmann La Roche
  • Especificos Stendhal
  • Baxter Healthcare
  • Barr Laboratories
  • Aphios
  • Acacia Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
  1. 2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
  2. 2.2 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Drivers
  3. 2.3 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Opportunities and Challenges
  4. 2.4 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Restraints
3 Chemotheraphy-induced Nausea and Vomitting Treatment Market by Company
  1. 3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Ranking (2024-2026)
  4. 3.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Product Type and Application
  6. 3.6 Global Chemotheraphy-induced Nausea and Vomitting Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Chemotheraphy-induced Nausea and Vomitting Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Chemotheraphy-induced Nausea and Vomitting Treatment Market by Type
  1. 4.1 Chemotheraphy-induced Nausea and Vomitting Treatment Type Introduction
  2. 4.1.1 5-HT3 Inhibitors
  3. 4.1.2 NK1 Inhibitors
  4. 4.1.3 Others
  5. 4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Type
  6. 4.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Type (2021-2032)
  8. 4.2.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type (2021-2032)
5 Chemotheraphy-induced Nausea and Vomitting Treatment Market by Application
  1. 5.1 Chemotheraphy-induced Nausea and Vomitting Treatment Application Introduction
  2. 5.1.1 Delayed Nausea and Vomitting Treatment
  3. 5.1.2 Acute Nausea and Vomitting Treatment
  4. 5.1.3 Anticipatory Nausea and Vomitting Treatment
  5. 5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Application
  6. 5.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application (2021-2032)
6 Chemotheraphy-induced Nausea and Vomitting Treatment Regional Value Analysis
  1. 6.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Country, 2025 VS 2032
7 Chemotheraphy-induced Nausea and Vomitting Treatment Country-level Value Analysis
  1. 7.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Chemotheraphy-induced Nausea and Vomitting Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Merck & Co
  8. 8.2.1 Merck & Co Company Information
  9. 8.2.2 Merck & Co Business Overview
  10. 8.2.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  12. 8.2.5 Merck & Co Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Tesaro
  20. 8.4.1 Tesaro Company Information
  21. 8.4.2 Tesaro Business Overview
  22. 8.4.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  24. 8.4.5 Tesaro Recent Developments
  25. 8.5 Orchid Healthcare
  26. 8.5.1 Orchid Healthcare Company Information
  27. 8.5.2 Orchid Healthcare Business Overview
  28. 8.5.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  30. 8.5.5 Orchid Healthcare Recent Developments
  31. 8.6 OPKO Health
  32. 8.6.1 OPKO Health Company Information
  33. 8.6.2 OPKO Health Business Overview
  34. 8.6.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  36. 8.6.5 OPKO Health Recent Developments
  37. 8.7 Mylan Pharmaceuticals
  38. 8.7.1 Mylan Pharmaceuticals Company Information
  39. 8.7.2 Mylan Pharmaceuticals Business Overview
  40. 8.7.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  42. 8.7.5 Mylan Pharmaceuticals Recent Developments
  43. 8.8 Mundipharma
  44. 8.8.1 Mundipharma Company Information
  45. 8.8.2 Mundipharma Business Overview
  46. 8.8.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  48. 8.8.5 Mundipharma Recent Developments
  49. 8.9 Heron Therapeutics
  50. 8.9.1 Heron Therapeutics Company Information
  51. 8.9.2 Heron Therapeutics Business Overview
  52. 8.9.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  54. 8.9.5 Heron Therapeutics Recent Developments
  55. 8.10 Helsinn
  56. 8.10.1 Helsinn Company Information
  57. 8.10.2 Helsinn Business Overview
  58. 8.10.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  60. 8.10.5 Helsinn Recent Developments
  61. 8.11 F.Hoffmann La Roche
  62. 8.11.1 F.Hoffmann La Roche Company Information
  63. 8.11.2 F.Hoffmann La Roche Business Overview
  64. 8.11.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  66. 8.11.5 F.Hoffmann La Roche Recent Developments
  67. 8.12 Especificos Stendhal
  68. 8.12.1 Especificos Stendhal Company Information
  69. 8.12.2 Especificos Stendhal Business Overview
  70. 8.12.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  72. 8.12.5 Especificos Stendhal Recent Developments
  73. 8.13 Baxter Healthcare
  74. 8.13.1 Baxter Healthcare Company Information
  75. 8.13.2 Baxter Healthcare Business Overview
  76. 8.13.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  78. 8.13.5 Baxter Healthcare Recent Developments
  79. 8.14 Barr Laboratories
  80. 8.14.1 Barr Laboratories Company Information
  81. 8.14.2 Barr Laboratories Business Overview
  82. 8.14.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  84. 8.14.5 Barr Laboratories Recent Developments
  85. 8.15 Aphios
  86. 8.15.1 Aphios Company Information
  87. 8.15.2 Aphios Business Overview
  88. 8.15.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  90. 8.15.5 Aphios Recent Developments
  91. 8.16 Acacia Pharma
  92. 8.16.1 Acacia Pharma Company Information
  93. 8.16.2 Acacia Pharma Business Overview
  94. 8.16.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product Portfolio
  96. 8.16.5 Acacia Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst